NZ515048A - 1,5-benzodiazepine derivatives - Google Patents

1,5-benzodiazepine derivatives

Info

Publication number
NZ515048A
NZ515048A NZ515048A NZ51504800A NZ515048A NZ 515048 A NZ515048 A NZ 515048A NZ 515048 A NZ515048 A NZ 515048A NZ 51504800 A NZ51504800 A NZ 51504800A NZ 515048 A NZ515048 A NZ 515048A
Authority
NZ
New Zealand
Prior art keywords
phenyl
benzodiazepine derivatives
carbamoylmethyl
diazepine
ureido
Prior art date
Application number
NZ515048A
Other languages
English (en)
Inventor
David Colclough
Anne Hodgson
Jerzy Ryszard Szewczyk
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NZ515048A publication Critical patent/NZ515048A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ515048A 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives NZ515048A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process
PCT/EP2000/003982 WO2000068209A2 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as cck-a receptor agonists

Publications (1)

Publication Number Publication Date
NZ515048A true NZ515048A (en) 2004-01-30

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515048A NZ515048A (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives

Country Status (21)

Country Link
EP (1) EP1212305A2 (zh)
JP (1) JP2002544200A (zh)
KR (1) KR20020012567A (zh)
CN (1) CN1161345C (zh)
AR (1) AR022044A1 (zh)
AU (1) AU4754800A (zh)
BR (1) BR0010338A (zh)
CA (1) CA2370801A1 (zh)
CO (1) CO5170461A1 (zh)
CZ (1) CZ20013988A3 (zh)
HK (1) HK1046138A1 (zh)
HU (1) HUP0201181A3 (zh)
IL (1) IL146124A0 (zh)
MX (1) MXPA01011267A (zh)
MY (1) MY138319A (zh)
NO (1) NO20015397L (zh)
NZ (1) NZ515048A (zh)
PE (1) PE20010110A1 (zh)
PL (1) PL351546A1 (zh)
TR (1) TR200103169T2 (zh)
WO (1) WO2000068209A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin

Also Published As

Publication number Publication date
TR200103169T2 (tr) 2002-04-22
AU4754800A (en) 2000-11-21
CN1161345C (zh) 2004-08-11
IL146124A0 (en) 2002-07-25
NO20015397D0 (no) 2001-11-05
WO2000068209A2 (en) 2000-11-16
KR20020012567A (ko) 2002-02-16
MY138319A (en) 2009-05-29
CN1362949A (zh) 2002-08-07
EP1212305A2 (en) 2002-06-12
CO5170461A1 (es) 2002-06-27
MXPA01011267A (es) 2002-05-06
JP2002544200A (ja) 2002-12-24
HUP0201181A3 (en) 2003-10-28
BR0010338A (pt) 2002-02-13
CA2370801A1 (en) 2000-11-16
PL351546A1 (en) 2003-05-05
CZ20013988A3 (cs) 2002-02-13
NO20015397L (no) 2001-11-05
HK1046138A1 (zh) 2002-12-27
PE20010110A1 (es) 2001-03-05
AR022044A1 (es) 2002-09-04
WO2000068209A3 (en) 2001-03-01
HUP0201181A2 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
CA2191871A1 (en) Piperazine derivatives as 5ht1a antagonists
GB0004297D0 (en) 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
BG105177A (en) Novel substituted pyrazole derivatives
AU1120599A (en) New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
BG105515A (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
HUP0105491A2 (en) Use of 3-[1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido]-2,3,4,5-tetrahydro-2-oxo-1h-benz(b)azepine-1-acetic acid derivatives for manufacture of a medicament for treating hypertension
EE04491B1 (et) (+)-nortsisapriidi kasutamine
GB9502644D0 (en) Heterocyclic derivatives
CA2248317A1 (en) Anticonvulsant enantiomeric amino acid derivatives
NZ270181A (en) Use of benzothiophene derivatives for inhibiting central nervous system problems in post-menopausal women
NZ515048A (en) 1,5-benzodiazepine derivatives
UA41353C2 (uk) Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність
NZ332545A (zh)
ES2036137A1 (es) Procedimiento para la preparacion de la nueva 1-(3-clorofenil)-4-hidroximetil-7,8-dimetoxi-5h-2,3-benzodiacepina y de sus sales de adicion acida.
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
FR2804322B1 (fr) Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
MY119140A (en) Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
HU9701325D0 (en) New 2,3-benzodiazepine derivatives
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
BG104394A (en) Indole derivative applicable as endotheliium receptor antagonist
ATE220665T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
HUP9900916A2 (hu) Benzotiofénszármazékok felhasználása az érszövetek kalciumvezetékeit antagonizáló hatású gyógyszerkészítmények előállítására
MX9704621A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su preparacion, medicamentos que contienen estos compuestos, y su utilizacion.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed